Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
Open accessThe DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Abstract
Growing evidence suggests that nonalcoholic fatty liver disease is associated with an increased risk of cardiovascular disease beyond that conferred by established risk factors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“NAFLD is an established risk factor for CVD and so increases the risk of cardiovascular complications in T2D patients.214,215”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [215]
Citations
Cites
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Inflammation and insulin resistance
Shoelson, S. E. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29069 · Cited by 4,769
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890
Long-term follow-up of patients with NAFLD and elevated liver enzymes
Ekstedt, M., Franzén, L. E., Mathiesen, U. L., Thorelius, L., Holmqvist, M., Bodemar, G., & Kechagias, S. (2006) · Hepatology · doi:10.1002/hep.21327 · Cited by 2,302
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827
Obesity, Inflammation, and Insulin Resistance
Shoelson, S. E., Herrero, L., & Naaz, A. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.059 · Cited by 1,806
The development of a comorbidity index with physical function as the outcome
GROLL, D., TO, T., BOMBARDIER, C., & WRIGHT, J. (2005) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2004.10.018 · Cited by 1,198
Disordered lipid metabolism and the pathogenesis of insulin resistance.
Savage, D. B., Petersen, K. F., & Shulman, G. I. (2007) · Physiological Reviews · doi:10.1152/physrev.00024.2006 · Cited by 1,107
Toll-like Receptor 4 Polymorphisms and Atherogenesis
Kiechl, S., Lorenz, E., Reindl, M., Wiedermann, C. J., Oberhollenzer, F., Bonora, E., Willeit, J., & Schwartz, D. A. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012673 · Cited by 1,024
Self-citationTargher, G., Bertolini, L., Padovani, R., Rodella, S., Tessari, R., Zenari, L., Day, C., & Arcaro, G. (2007) · Diabetes Care · doi:10.2337/dc06-2247 · Cited by 992
Self-citationPetersen, K. F., Dufour, S., Befroy, D., Lehrke, M., Hendler, R. E., & Shulman, G. I. (2005) · Diabetes · doi:10.2337/diabetes.54.3.603 · Cited by 911
Fatty Liver: A Novel Component of the Metabolic Syndrome
Kotronen, A., & Yki-Järvinen, H. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.147538 · Cited by 797
The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome
Petersen, K. F., Dufour, S., Savage, D. B., Bilz, S., Solomon, G., Yonemitsu, S., Cline, G. W., Befroy, D., Zemany, L., Kahn, B. B., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705408104 · Cited by 759
Musso, G., Gambino, R., De Michieli, F., Cassader, M., Rizzetto, M., Durazzo, M., Fagà, E., Silli, B., & Pagano, G. (2003) · Hepatology · doi:10.1053/jhep.2003.50132 · Cited by 759
Decreased Survival of Subjects With Elevated Liver Function Tests During A 28-Year Follow-Up
Söderberg, C., Stål, P., Askling, J., Glaumann, H., Lindberg, G., Marmur, J., & Hultcrantz, R. (2010) · Hepatology · doi:10.1002/hep.23314 · Cited by 754
Histopathology of Pediatric Nonalcoholic Fatty Liver Disease * #
Schwimmer, J. B., Behling, C., Newbury, R., Deutsch, R., Nievergelt, C., Schork, N. J., & Lavine, J. E. (2005) · Hepatology · doi:10.1002/hep.20842 · Cited by 747
Long-Term Follow-Up of Patients With Nonalcoholic Fatty Liver
Rafiq, N., Bai, C., Fang, Y., Srishord, M., McCullough, A., Gramlich, T., & Younossi, Z. M. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.11.005 · Cited by 729
Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease†
Villanova, N., Moscatiello, S., Ramilli, S., Bugianesi, E., Magalotti, D., Vanni, E., Zoli, M., & Marchesini, G. (2005) · Hepatology · doi:10.1002/hep.20781 · Cited by 629
A Stress Signaling Pathway in Adipose Tissue Regulates Hepatic Insulin Resistance
Sabio, G., Das, M., Mora, A., Zhang, Z., Jun, J. Y., Ko, H. J., Barrett, T., Kim, J. K., & Davis, R. J. (2008) · Science · doi:10.1126/science.1160794 · Cited by 604
Non-alcoholic fatty liver disease: The mist gradually clears
de Alwis, N. M. W., & Day, C. P. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.01.009 · Cited by 603
Self-citationIncreased Hepatic and Circulating Interleukin-6 Levels in Human Nonalcoholic Steatohepatitis
Wieckowska, A., Papouchado, B. G., Li, Z., Lopez, R., Zein, N. N., & Feldstein, A. E. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01774.x · Cited by 597
Targher, G., Bertolini, L., Rodella, S., Tessari, R., Zenari, L., Lippi, G., & Arcaro, G. (2007) · Diabetes Care · doi:10.2337/dc07-0349 · Cited by 579
Self-citationTargher, G., Bertolini, L., Poli, F., Rodella, S., Scala, L., Tessari, R., Zenari, L., & Falezza, G. (2005) · Diabetes · doi:10.2337/diabetes.54.12.3541 · Cited by 574
Self-citationRuttmann, E., Brant, L. J., Concin, H., Diem, G., Rapp, K., Ulmer, H., & the Vorarlberg Health Monitoring and Promotion Program Study Group (2005) · Circulation · doi:10.1161/circulationaha.105.552547 · Cited by 556
Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease
Hamaguchi, M. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i10.1579 · Cited by 542
Causes and Metabolic Consequences of Fatty Liver
Stefan, N., Kantartzis, K., & Häring, H.-U. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0009 · Cited by 532
Lee, D. S., Evans, J. C., Robins, S. J., Wilson, P. W., Albano, I., Fox, C. S., Wang, T. J., Benjamin, E. J., D’Agostino, R. B., & Vasan, R. S. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000251993.20372.40 · Cited by 530
Long term prognosis of fatty liver: risk of chronic liver disease and death
Dam-Larsen, S., Franzmann, M., Andersen, I. B., Christoffersen, P., Jensen, L. B., Sørensen, T. I. A., Becker, U., & Bendtsen, F. (2004) · Gut · doi:10.1136/gut.2003.019984 · Cited by 508
Insulin resistance, inflammation, and non-alcoholic fatty liver disease
Tilg, H., & Moschen, A. R. (2008) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2008.08.005 · Cited by 473
Schindhelm, R. K., Dekker, J. M., Nijpels, G., Bouter, L. M., Stehouwer, C. D. A., Heine, R. J., & Diamant, M. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.04.006 · Cited by 420
Thuy, S., Ladurner, R., Volynets, V., Wagner, S., Strahl, S., Königsrainer, A., Maier, K.-P., Bischoff, S. C., & Bergheim, I. (2008) · The Journal of Nutrition · doi:10.1093/jn/138.8.1452 · Cited by 412
Sookoian, S., & Pirola, C. J. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.06.012 · Cited by 406
Targher, G., Bertolini, L., Padovani, R., Rodella, S., Zoppini, G., Zenari, L., Cigolini, M., Falezza, G., & Arcaro, G. (2006) · Diabetes Care · doi:10.2337/dc06-0135 · Cited by 401
Self-citationDay, C. P. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.017 · Cited by 395
Self-citationNonalcoholic Fatty Liver Disease Is Associated With Carotid Atherosclerosis: A Case–Control Study
Brea, A., Mosquera, D., Martín, E., Arizti, A., Cordero, J. L., & Ros, E. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000160613.57985.18 · Cited by 387
Targher, G., Marra, F., & Marchesini, G. (2008) · Diabetologia · doi:10.1007/s00125-008-1135-4 · Cited by 378
Self-citationObesity-Associated Liver Disease
Marchesini, G., Moscatiello, S., Di Domizio, S., & Forlani, G. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1399 · Cited by 359
Ruhl, C. E., & Everhart, J. E. (2009) · Gastroenterology · doi:10.1053/j.gastro.2008.10.052 · Cited by 352
Aminotransferase Levels and 20-Year Risk of Metabolic Syndrome, Diabetes, and Cardiovascular Disease
Goessling, W., Massaro, J. M., Vasan, R. S., D'Agostino, R. B., Ellison, R. C., & Fox, C. S. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.09.018 · Cited by 330
Suspected Nonalcoholic Fatty Liver Disease and Mortality Risk in a Population-Based Cohort Study
Dunn, W., Xu, R., Wingard, D. L., Rogers, C., Angulo, P., Younossi, Z. M., & Schwimmer, J. B. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.02034.x · Cited by 325
Yoneda, M., Mawatari, H., Fujita, K., Iida, H., Yonemitsu, K., Kato, S., Takahashi, H., Kirikoshi, H., Inamori, M., Nozaki, Y., et al. (2007) · Journal of Gastroenterology · doi:10.1007/s00535-007-2060-x · Cited by 294
Bajaj, M., Suraamornkul, S., Pratipanawatr, T., Hardies, L. J., Pratipanawatr, W., Glass, L., Cersosimo, E., Miyazaki, Y., & DeFronzo, R. A. (2003) · Diabetes · doi:10.2337/diabetes.52.6.1364 · Cited by 290
Fraser, A., Harris, R., Sattar, N., Ebrahim, S., Smith, G. D., & Lawlor, D. A. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.152298 · Cited by 277
The adipocyte as an active participant in energy balance and metabolism
Badman, M. K., & Flier, J. S. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.058 · Cited by 256
Hepatic steatosis is associated with an increased risk of carotid atherosclerosis
Völzke, H. (2005) · World Journal of Gastroenterology · doi:10.3748/wjg.v11.i12.1848 · Cited by 248
Haring, R., Wallaschofski, H., Nauck, M., Dörr, M., Baumeister, S. E., & Völzke, H. (2009) · Hepatology · doi:10.1002/hep.23135 · Cited by 245
Benefits of lifestyle modification in NAFLD
Harrison, S. A., & Day, C. P. (2007) · Gut · doi:10.1136/gut.2006.112094 · Cited by 240
Self-citationTargher, G., Bertolini, L., Padovani, R., Rodella, S., Zoppini, G., Pichiri, I., Sorgato, C., Zenari, L., & Bonora, E. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.04.030 · Cited by 235
Self-citationThe metabolic syndrome and cardiovascular disease
Bonora, E. (2006) · Annals of Medicine · doi:10.1080/07853890500401234 · Cited by 231
Self-citationLee, D.-H. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl086 · Cited by 224
NASH Predicts Plasma Inflammatory Biomarkers Independently of Visceral Fat in Men
Targher, G., Bertolini, L., Rodella, S., Lippi, G., Franchini, M., Zoppini, G., Muggeo, M., & Day, C. P. (2008) · Obesity · doi:10.1038/oby.2008.64 · Cited by 214
Self-citationPerseghin, G., Lattuada, G., De Cobelli, F., Esposito, A., Belloni, E., Ntali, G., Ragogna, F., Canu, T., Scifo, P., Del Maschio, A., et al. (2008) · Hepatology · doi:10.1002/hep.21983 · Cited by 210
Carotid Artery Intima-media Thickness in Nonalcoholic Fatty Liver Disease
Fracanzani, A. L., Burdick, L., Raselli, S., Pedotti, P., Grigore, L., Santorelli, G., Valenti, L., Maraschi, A., Catapano, A., & Fargion, S. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.08.041 · Cited by 209
Relation of Nonalcoholic Hepatic Steatosis to Early Carotid Atherosclerosis in Healthy Men
Targher, G., Bertolini, L., Padovani, R., Zenari, L., Zoppini, G., & Falezza, G. (2004) · Diabetes Care · doi:10.2337/diacare.27.10.2498 · Cited by 197
Self-citationMcKimmie, R. L., Daniel, K. R., Carr, J. J., Bowden, D. W., Freedman, B. I., Register, T. C., Hsu, F.-C., Lohman, K. K., Weinberg, R. B., & Wagenknecht, L. E. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.02188.x · Cited by 189
Lautamäki, R., Borra, R., Iozzo, P., Komu, M., Lehtimäki, T., Salmi, M., Jalkanen, S., Airaksinen, K. E. J., Knuuti, J., Parkkola, R., et al. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00604.2005 · Cited by 170
Statins and hepatic steatosis: Perspectives from the Dallas Heart Study
Browning, J. D. (2006) · Hepatology · doi:10.1002/hep.21248 · Cited by 162
Goland, S., Shimoni, S., Zornitzki, T., Knobler, H., Azoulai, O., Lutaty, G., Melzer, E., Orr, A., Caspi, A., & Malnick, S. (2006) · Journal of Clinical Gastroenterology · doi:10.1097/01.mcg.0000225668.53673.e6 · Cited by 162
Targher, G., Bertolini, L., Padovani, R., Rodella, S., Arcaro, G., & Day, C. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.01.021 · Cited by 162
Self-citationKim, H. C., Kim, D. J., & Huh, K. B. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.09.012 · Cited by 147
Targher, G., Chonchol, M., Miele, L., Zoppini, G., Pichiri, I., & Muggeo, M. (2009) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0029-1222606 · Cited by 145
Self-citationSonographic fatty liver, overweight and ischemic heart disease
Lin, Y.-C. (2005) · World Journal of Gastroenterology · doi:10.3748/wjg.v11.i31.4838 · Cited by 141
Yun, K. E., Shin, C. Y., Yoon, Y. S., & Park, H. S. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.12.012 · Cited by 134
Wannamethee, S. G., LENNON, L. T., & Shaper, A. G. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.01.019 · Cited by 118
Petit, J., Guiu, B., Terriat, B., Loffroy, R., Robin, I., Petit, V., Bouillet, B., Brindisi, M., Duvillard, L., Hillon, P., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0541 · Cited by 112
Liver: an alarm for the heart?
Mirbagheri, S. A., Rashidi, A., Abdi, S., Saedi, D., & Abouzari, M. (2007) · Liver International · doi:10.1111/j.1478-3231.2007.01531.x · Cited by 78
Postprandial Lipemia Associates with Liver Fat Content
Matikainen, N., Mänttäri, S., Westerbacka, J., Vehkavaara, S., Lundbom, N., Yki-Järvinen, H., & Taskinen, M.-R. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0187 · Cited by 76
Lincoff, A. M., Wolski, K., Nicholls, S. J., & Nissen, S. E. (2007) · JAMA · doi:10.1001/jama.298.10.1180 · Cited by 52
Cited by
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,803
“Statin use in patients with NAFLD and NASH Patients with NAFLD and NASH are at increased risk for cardiovascular disease and several studies have established cardiovascular disease as their most common cause of death.(6) Patients with NAFLD should be risk stratified for cardiovascular disease, and their cardiovascular…”
BackgroundByrne, C. D., & Targher, G. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.12.012 · Cited by 3,042
“It is likely that there is a pathogenic ‘‘cross-talk’’ between the liver and the expanded and ‘dysfunctional’ (inflamed) adipose tissue [1,18,58,72,75].”
BackgroundInfluentialSelf-citationEkstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287
“NASH is considered the more aggressive part of the NAFLD spectrum, associated with progressive fibrosis as well as higher risk of cardiovascular disease.(7,8) Today, NAFLD is the third most common cause for need of liver transplantation, and on the trajectory of becoming the most common cause.”
BackgroundA phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis
Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309000 · Cited by 2,084
Metadata
- Authors
- Targher, G., Day, C. P., & Bonora, E.
- Affiliations
- University of Verona (IT)
- Newcastle University (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-09-30
- Volume
- 363
- Issue
- 14
- Pages
- 1341-1350
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2120397203
- Cited by
- 1,907
- References
- 71
- Citations by year
- 2026: 31 · 2025: 99 · 2024: 95 · 2023: 109 · 2022: 115 · 2021: 143 · 2020: 175 · 2019: 137 · 2018: 103 · 2017: 125 · 2016: 150 · 2015: 157 · 2014: 138 · 2013: 133 · 2012: 100
- FWCI
- 11.91
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- non-alcoholic fatty liver disease, cardiovascular disease, cardiovascular risk, comorbidities, risk factors
- MeSH terms
- Biopsy, Cardiovascular Diseases, Carotid Arteries, Fatty Liver, Humans, Insulin Resistance, Liver, Risk Factors, Ultrasonography, Incidence, Obesity, Abdominal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.